Modeling and Simulation Archives | Certara

Dizal Pharma

Case Study

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…

CertaraOctober 2, 2025

Blog

Best Practices in Clinical Pharmacology Gap Analysis

September 19, 2025 Submitting your New Drug Application (NDA) to the FDA is the ultimate…

CertaraSeptember 19, 2025

Announcement

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraSeptember 17, 2025

Conference

Redefining Every Stage of Investment (RESI) Seed to Exit

CertaraSeptember 5, 2025

Conference

The Pharmacometrics Africa Conference 2025 (PMXAC-2025)

CertaraSeptember 4, 2025

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

CertaraSeptember 4, 2025

Webinar

The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape

CertaraSeptember 3, 2025

Webinar

Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH)

Danielle PillsburyAugust 29, 2025

Conference

BioTechX US 2025

– – Booth

Simona ColucciAugust 15, 2025

Blog

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…

CertaraJuly 31, 2025

© 2025 Certara. All Rights Reserved. | Legal | Privacy policy